Metagenics has appointed Patrick Sly as Chief Executive Officer, effective immediately, marking a significant leadership transition for the professional-grade supplement company. Current President and CEO Pat Smallcombe, who has guided Metagenics through a period of strong growth since 2023, will move into the role of Co-Chair of the Board. Metagenics continues to be backed by Gryphon Investors, a leading middle-market private investment firm.
The move pairs continuity at the board level with a CEO who brings extensive experience in medical nutrition, healthcare professional partnerships, and large-scale consumer health businesses. For healthcare practitioners, retailers, and distributors, the appointment signals Metagenics’ intention to accelerate its next phase of growth while maintaining a strong focus on science, quality, and professional channels.
Leadership transition with continuity
Under Smallcombe’s leadership, Metagenics has strengthened its position in the rapidly expanding professional supplements segment, invested in clinically tested formulations, and deepened its relationships with healthcare professionals. His transition to Co-Chair of the Board ensures strategic continuity and ongoing stewardship at the governance level, even as day-to-day leadership passes to Sly.
Commenting on the transition, Ryan Fagan, Deal Partner in Gryphon’s Consumer Group, emphasised both continuity and fresh leadership:
“With Patrick’s deep experience in medical nutrition, partnerships with healthcare professionals, and leadership of global businesses, I couldn’t imagine a stronger candidate to succeed Pat Smallcombe’s successful tenure. Patrick’s leadership style focuses on integrity, innovation, and collaboration, an ideal fit for Metagenics’ culture.”
For stakeholders across the health and wellness ecosystem, the combination of Smallcombe’s board role and Sly’s operational leadership sets Metagenics up for a deliberate, well-planned handover rather than a disruptive shift.
A track record of global transformation
Sly brings to Metagenics a proven record of transforming large consumer health and nutrition businesses into sustained value creators. Most recently, he served as Global President of Reckitt’s US$8-billion Consumer Health division, where he led the portfolio to industry-leading profitability, renewed market share momentum, and durable, long-term growth.
Before that, he served as Global President of Reckitt’s US$3-billion Nutrition business, where he delivered a major global turnaround that strengthened margins, accelerated growth, and restored competitiveness across key markets.
Having lived and led in five countries, Sly brings a high degree of cultural fluency, adaptability, and global strategic insight. These qualities have enabled him to inspire diverse teams, navigate complex regulatory and market environments, and build resilient, performance-driven organisations that can adapt quickly to evolving health trends and consumer expectations.
Widely recognised for architecting transformations that elevate brands, expand margins, and create meaningful shareholder value, Sly is known as a leader who combines category expertise with crisis-tested judgement and a strong focus on people and culture.
He earned his MBA from Washington University in St. Louis’ Olin Business School and his Bachelor of Science in Business from Indiana University’s Kelley School of Business.
Positioning Metagenics for the next phase of growth
The appointment comes at a time when the professional supplements category is undergoing rapid change. Healthcare professionals and their patients are demanding more clinically substantiated products, clearer evidence on efficacy and safety, and stronger support around practice integration and patient adherence. At the same time, competition from both practitioner-only and direct-to-consumer brands continues to intensify.
Metagenics’ combination of scientific focus, professional-only distribution strength, and private-equity backing positions the company to invest further in product innovation, clinical research, digital tools for practitioners, and global expansion. Sly’s experience leading large portfolios, managing complex supply chains, and steering global teams is expected to support these ambitions.
“I’m thrilled to be joining Metagenics at such an exciting time,” said Sly. “The professional segment of the supplements category has tremendous growth potential, and Metagenics’ outstanding brand and clinically tested product line position the company for continued success. I’m especially impressed by the very strong team and solid foundation that Pat Smallcombe has built, and I look forward to working with the organisation to drive the next phase of growth.”
For Canadian natural health retailers, clinics, and practitioners, this leadership change underscores the increasing sophistication of the professional supplements space. As companies like Metagenics bring in globally seasoned executives, the bar continues to rise on quality, evidence, and execution—both in the back office and at the practitioner’s front desk.
